NCT06298643Completed
Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to describe the treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs of lower-risk myelodysplastic syndromes patients in Japan.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 177 (actual)
- First submitted
- 1 Mar 2024
- Start date
- 22 Dec 2023
- Primary completion date
- 9 Jul 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Myelodysplastic syndromes
- NCT number
- NCT06298643
What you commit to
- Study type: Observational
- Participants enrolled: 177
- From 22 Dec 2023 to the primary completion date, 9 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants who have a look back period \<30 days from initial myelodysplastic syndrome diagnosis date
Age
- Participants \<18 years of age at index date
Other
- Participants not meeting the inclusion criteria
Who the study is looking for
- Participants with at least one definitive myelodysplastic syndrome (MDS) diagnosis as per the 10th Revision of the International Statistical Classification of Diseases and Related Health Problems (MDS; ICD10: D46.X) between 01-May-2017 and 31-Jan-2022
- Participants with confirmed low-risk MDS by International Prognostic Scoring System (IPSS) or Revised International Prognostic Scoring System (IPSS-R) during baseline as follows:
- Record of low (0 points) or intermediate-1 (\>0 to 1 point) MDS according to IPSS scoring; or
- Record of very low (≤1.5), low (\>1.5-3), or intermediate (\>3-4.5) MDS according to IPSS-R scoring; or
- Mention of very low, low, intermediate, intermediate-1, or lower risk MDS in the Electronic Medical Records (EMR)
- Participants with a record of a confirmed bone marrow procedure (bone marrow aspiration code D404-00 and/or bone marrow biopsy code D404-02) during baseline period
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mebix, Inc Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.